X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
The net proceeds will be used for the advancement of company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bradbury Asset Management
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 26, 2024
Details:
IGC-AD1, a combination medicine with a CB1 receptor partial agonist with anti-neuroinflammatory properties. It is under phase 2 clinical development for the treatment of dementia due to Alzheimer’s.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research, with IGC-AD1, a low-dose tetrahydrocannabinol based formulation, currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to Alzheimer’s.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: O-Bank Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 07, 2023
Details:
The funds will support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1 (tetrahydrocannabinol), the Company’s promising investigational drug candidate designed to address agitation in dementia caused by Alzheimer's disease.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bradbury Asset Management
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 06, 2023
Details:
This is a phase I Multiple Ascending Dose (MAD) study to evaluate safety and tolerability of IGC-AD1 (tetrahydrocannabinol) in subjects with AD. Twelve subjects will be enrolled. Three different ascending doses of the study product will be given: low, medium and high doses.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Results from a new Cleveland Clinic-led study suggest that melatonin, a hormone that regulates the sleep-wake cycle and is commonly used as an over-the-counter sleep aid, may be a viable treatment option for COVID-19.
Lead Product(s): Melatonin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Kinderlyte's Herbal Sleep Supplement is a doctor-formulated, drug-free sleep aid that uses a proprietary blend of melatonin and calming botanicals such as chamomile, passionflower, and lemon balm to support sleep.
Lead Product(s): Melatonin,Apigenin
Therapeutic Area: Sleep Product Name: Kinderlyte Sleep
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Cleveland Clinic compared COVID-19 with the coronavirus that caused the SARS outbreak of 2003 using a technique called “network proximity analysis” to identify combinations of existing drugs.
Lead Product(s): Melatonin,Mercaptopurine,Sirolimus
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
